<DOC>
	<DOCNO>NCT01511250</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability dengue vaccine administer subcutaneously healthy adult child . In addition antibody response four dengue virus serotypes evaluate .</brief_summary>
	<brief_title>Study Investigate Safety Immunogenicity Tetravalent Chimeric Dengue Vaccine Healthy Volunteers Between Ages 1.5 - 45 Years</brief_title>
	<detailed_description />
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>In good health Normal laboratory value screen Abnormal ECG History significant dermatologic ( skin ) disease within last 6 month Diabetes mellitus History immunodeficiency History recur headache migraine Hypersensitivity vaccine Use amphetamine , opiate , cannabinoids History alcohol abuse Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>normal healthy adult child</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>active vaccine</keyword>
	<keyword>placebo</keyword>
	<keyword>Dengue virus vaccine</keyword>
	<keyword>Immune response</keyword>
</DOC>